ClinicalTrials.gg
CompletedNCT00274742Updated Jan 16, 2015Results posted

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

A Phase 1 interventional study of Blinatumomab (MT103) in Non-Hodgkin's Lymphoma, Relapsed, sponsored by Amgen Research (Munich) GmbH. Completed at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.

Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Lymphoma, Non-Hodgkin by Amgen — none open to participants now, none under way, none of them phase 3. Lymphoma, Non-Hodgkin · Amgen.

Enrollment
4th of 15
76 · median 39
Started
2004
the only one that year
Phase 1
7 of 20
none open now
Registered
9th of 20
by date

Among the 20 studies in Lymphoma, Non-Hodgkin by Amgen, this one is the 4th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2004, is one of 7 in phase 1, and was the 9th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 20 studies in Lymphoma, Non-Hodgkin by Amgen is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Lymphoma, Non-Hodgkin by Amgen as a file.
02

Study summary

The purpose of this study is to determine whether a continuous infusion of Blinatumomab (MT103) is safe in the treatment of relapsed Non-Hodgkin's Lymphoma.

Furthermore, the study is intended to provide pharmacokinetic and pharmacodynamic data of Blinatumomab as well as to get first indication of tumour activity.

Read the detailed description

Non-Hodgkin's Lymphoma (NHL) represents the 6th most common cancer. Globally, around 165,000 new cases are diagnosed each year, with approximately 90,000 deaths per year. The vast majority of NHLs are B-cell derived (90%) and express common B-cell antigens such as CD19, CD20 and CD22. NHL can be divided into indolent (low-grade) and aggressive (high-grade) lymphomas. Still almost all patients with advanced stage indolent disease will die from their disease. Therefore, a high medical need exists to develop novel agents that further improve the survival of NHL patients.

Blinatumomab (MT103) is a bispecific antibody derivative, anti-CD19 x anti-CD3, designed to link B-cells and T-cells resulting in T-cell activation and a cytotoxic T-cell response against CD19+ cells. Data of prior phase I studies show evidence of biological activity in humans. In vitro and ex-vivo data suggest that a longterm presence of the drug in target tissues may provide antitumour activity.

The study investigates the safety and tolerability of different doses of Blinatumomab administration in a continuous infusion regimen. Maximum tolerated dose (MTD) will be defined in a classical 3+3 dose escalation regimen.

03

Conditions studied

  • Non-Hodgkin's Lymphoma, Relapsed

Keywords

  • Non-Hodgkin's Lymphoma
  • Cancer immunotherapy
  • Monoclonal antibody
  • anti-CD19
  • anti-CD3
  • BiTE
  • Blinatumomab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with first or later relapse of histologically (World Health Organisation classification) confirmed:

    • follicular lymphoma (grade I/II)
    • marginal zone lymphoma
    • lymphoplasmocytic lymphoma
    • mantle cell lymphoma
    • diffuse large B-cell lymphoma
    • small lymphocytic lymphoma requiring therapy and not eligible for curative treatment
  2. (at least one lesion >= 1.5 cm) documented by computed tomography (CT) scan
  3. Age >= 18 years
  4. (ECOG) performance status \<=2
  5. of at least 6 months
  6. Ability to understand the patient information and form
  7. Signed and dated written informed consent is available
  8. B:T cell ratio (Fluorescence-Activated Cell Sorter [FACS] analysis results by central lab) available before study entry.

Exclusion criteria

Exclusion Criteria:

  1. Any other NHL not listed in inclusion criterion 1
  2. Abnormal laboratory values as defined below:

    • Peripheral lymphocyte count > 20 x 10\^9/L
    • counts ≤ 75,000/µL
    • level ≤ 9 g/dL
    • Venous pH value out of normal range or oxygen saturation ≤ 90%
  3. Known or suspected central nervous system (CNS) involvement by NHL
  4. a)History of or current relevant CNS pathology as epilepsy, seizure, paresis,aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis b)Evidence for presence of inflammatory lesions and/or vasculitis on cerebral MRI
  5. stem cell transplantation within 12 weeks prior to study entry
  6. Allogeneic stem cell transplantation
  7. Cancer chemotherapy within 4 weeks prior to study entry
  8. Radiotherapy within 4 weeks prior to study entry
  9. Treatment with rituximab within 4 weeks prior to study entry
  10. Prior treatment with alemtuzumab 12 weeks prior to study entry
  11. Treatment with any agent within 12 weeks prior to study entry
  12. for any of the concomitant medications
  13. Abnormal renal or hepatic function as defined below:

    • (AST; SGOT) and/or alanine aminotransferase (ALT; SGPT) >= 2 x (ULN)
    • total >= 1.5 x ULN
    • serum creatinine >= 2 x ULN
    • \< 50mL/min
  14. Indication of hypercoagulative state as defined below:

    -antithrombin activity \<LLN

  15. Presence of human anti-murine antibodies (HAMA) or known to immunoglobulins
  16. History of other than B-cell lymphoma within 5 years prior to study entry, with the exception of basal cell carcinoma of the skin or carcinoma in situ of the cervix
  17. Active infection / not yet recovered from recent infection; known bacteriemia
  18. Any concurrent disease or medical condition that is deemed to interfere with the conduct of the study as judged by the investigator
  19. Regular dose of during the four weeks prior to D1 of this study or anticipated need of corticosteroids exceeding prednisone 20 mg/day or equivalent, or any other therapy within 4 weeks prior to study entry
  20. Known infection with (HIV) or chronic infection with or virus
  21. Pregnant or nursing women, or women of not willing to use an effective form of during participation in the study and at least three months thereafter. Male patients not willing to ensure that during the study and at least three months thereafter no fathering takes place.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Patients received blinatumomab as continuous intravenous infusion for 4 weeks. Participants with clinical benefit were permitted to continue for another 4 weeks for a total of 8 weeks. Participants with a clinical benefit 4 weeks after completion of the first cycle of treatment could also receive additional treatment approximately 3 months ater the end of infusion at the same dose level.

    Biological: Blinatumomab (MT103)

Interventions

  • Doses from 0.5 to 120 µg/m\^2/24hours by continuous intravenous infusion

    Also known as: Blinatumomab, MT103, AMG103, BLINCYTO™

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Participants reporting at least one occurence of any adverse event including clinical symptoms, laboratory abnormalities, serious adverse events, and treatment-limiting adverse events

    Time frame: From the first infusion of blinatumomab until the safety follow-up visit 2 weeks after end of the treatment period, including the consolidation and relapse periods. The median treatment duration was 33.24 days.

Secondary outcomes

  1. Serum Concentration of Blinatumomab

    The steady state serum concentration (Css), summarized as the observed concentrations collected at least 10 hours after the start of continuous intravenous infusion or within the sampling window at the end of infusion. Concentrations below the lower limit of quantitation (100 pg/mL) were excluded from analysis.

    Time frame: Up to 24 hours after the end of infusion.

  2. Objective Tumor Response According to the Cheson Criteria (Without Minimal Response)

    Tumor response was defined according to the Cheson criteria and assessed after 4 and 8 weeks of study treatment using computed tomography (CT) scan (neck, thorax and abdomen/pelvic to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Best clinical response is defined as the best response achieved during the course of the study, with response defined as: Complete Response, Complete Response Unconfirmed, Partial Response, Stable Disease, and Progressive Disease. In this analysis minimal response is set to stable disease as intended in the response categories according to the Cheson criteria. An independent external review by a radiologist (computed tomography scans) and a pathologist (biopsies) was performed to confirm response status. If no post-baseline tumor assessment was available, the overall clinical response was set to not available.

    Time frame: Assessed after 4 and 8 weeks of treatment

  3. Objective Tumor Response According to the Cheson Criteria (With Minimal Response)

    Tumor response was defined according to the Cheson criteria and assessed after 4 and 8 weeks of study treatment using computed tomography (CT) scan (neck, thorax and abdomen/pelvic to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Minimal response was treated as a separate response category in this analysis. Best clinical response was defined as the best response achieved during the course of the study, whereby the following order was applied: Complete Response, Complete Response Unconfirmed, Partial Response, Minimal Response, Stable Disease, and Progressive Disease. If no post-baseline tumor assessment was available, the overall clinical response was set to not available.

    Time frame: Assessed after 4 and 8 weeks of treatment

07

Results

Posted Jan 16, 2015

Participant flow

Participants were enrolled from 22 June 2004 through 18 July 2011

Participant flow — Overall Study
MilestoneBlinatumomab ≤ 5 µg/m²/dBlinatumomab 15 µg/m²/dBlinatumomab 30 µg/m²/dBlinatumomab 60 µg/m²/d FlatBlinatumomab 60 µg/m²/d StepBlinatumomab 90 µg/m²/d
Started121369324
Completed12544161
Not completed0825163
Withdrew: Adverse event0414123
Withdrew: Lost to follow-up000010
Withdrew: End of study000100
Withdrew: Disease progression011010
Withdrew: Other030020

Outcome measures

PrimaryNumber of Participants With Adverse Events

Participants reporting at least one occurence of any adverse event including clinical symptoms, laboratory abnormalities, serious adverse events, and treatment-limiting adverse events

Time frame:
From the first infusion of blinatumomab until the safety follow-up visit 2 weeks after end of the treatment period, including the consolidation and relapse periods. The median treatment duration was 33.24 days.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsBlinatumomab ≤ 5 µg/m²/dBlinatumomab 15 µg/m²/dBlinatumomab 30 µg/m²/dBlinatumomab 60 µg/m²/d FlatBlinatumomab 60 µg/m²/d StepBlinatumomab 90 µg/m²/d
Number of Participants With Adverse Events121369324
SecondarySerum Concentration of Blinatumomab

The steady state serum concentration (Css), summarized as the observed concentrations collected at least 10 hours after the start of continuous intravenous infusion or within the sampling window at the end of infusion. Concentrations below the lower limit of quantitation (100 pg/mL) were excluded from analysis.

Time frame:
Up to 24 hours after the end of infusion.
Reported as:
Mean · pg/mL
Serum Concentration of Blinatumomab
pg/mLBlinatumomab 5 µg/m²/dBlinatumomab 15 µg/m²/dBlinatumomab 30 µg/m²/dBlinatumomab 60 µg/m²/dBlinatumomab 90 µg/m²/d
Serum Concentration of Blinatumomab210 ± 84.9651 ± 3071210 ± 4762730 ± 9853490 ± 904
SecondaryObjective Tumor Response According to the Cheson Criteria (Without Minimal Response)

Tumor response was defined according to the Cheson criteria and assessed after 4 and 8 weeks of study treatment using computed tomography (CT) scan (neck, thorax and abdomen/pelvic to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Best clinical response is defined as the best response achieved during the course of the study, with response defined as: Complete Response, Complete Response Unconfirmed, Partial Response, Stable Disease, and Progressive Disease. In this analysis minimal response is set to stable disease as intended in the response categories according to the Cheson criteria. An independent external review by a radiologist (computed tomography scans) and a pathologist (biopsies) was performed to confirm response status. If no post-baseline tumor assessment was available, the overall clinical response was set to not available.

Time frame:
Assessed after 4 and 8 weeks of treatment
Reported as:
Number · participants
Objective Tumor Response According to the Cheson Criteria (Without Minimal Response)
participantsBlinatumomab ≤ 5 µg/m²/dBlinatumomab 15 µg/m²/dBlinatumomab 30 µg/m²/dBlinatumomab 60 µg/m²/d FlatBlinatumomab 60 µg/m²/d StepBlinatumomab 90 µg/m²/d
Complete response011351
Complete response unconfirmed000050
Partial response020561
Stable disease672071
Progressive disease632070
Not available001121
SecondaryObjective Tumor Response According to the Cheson Criteria (With Minimal Response)

Tumor response was defined according to the Cheson criteria and assessed after 4 and 8 weeks of study treatment using computed tomography (CT) scan (neck, thorax and abdomen/pelvic to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Minimal response was treated as a separate response category in this analysis. Best clinical response was defined as the best response achieved during the course of the study, whereby the following order was applied: Complete Response, Complete Response Unconfirmed, Partial Response, Minimal Response, Stable Disease, and Progressive Disease. If no post-baseline tumor assessment was available, the overall clinical response was set to not available.

Time frame:
Assessed after 4 and 8 weeks of treatment
Reported as:
Number · participants
Objective Tumor Response According to the Cheson Criteria (With Minimal Response)
participantsBlinatumomab ≤ 5 µg/m²/dBlinatumomab 15 µg/m²/dBlinatumomab 30 µg/m²/dBlinatumomab 60 µg/m²/d FlatBlinatumomab 60 µg/m²/d StepBlinatumomab 90 µg/m²/d
Complete response011351
Complete response unconfirmed000050
Partial response020561
Minimal response111021
Stable disease561050
Progressive disease632070
Not available001121

Adverse events

Collected over From the first infusion of blinatumomab until the safety follow-up visit 2 weeks after end of the treatment period, including the consolidation and relapse periods. The median treatment duration was 33.24 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinatumomab ≤ 5 µg/m²/d—8/12 (66.7%)12/12 (100%)
Blinatumomab 15 µg/m²/d—10/13 (76.9%)13/13 (100%)
Blinatumomab 30 µg/m²/d—6/6 (100%)6/6 (100%)
Blinatumomab 60 µg/m²/d Flat—9/9 (100%)9/9 (100%)
Blinatumomab 60 µg/m²/d Step—22/32 (68.8%)32/32 (100%)
Blinatumomab 90 µg/m²/d—4/4 (100%)4/4 (100%)
Blinatumomab Overall—59/76 (77.6%)76/76 (100%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventBlinatumomab ≤ 5 µg/m²/dBlinatumomab 15 µg/m²/dBlinatumomab 30 µg/m²/dBlinatumomab 60 µg/m²/d FlatBlinatumomab 60 µg/m²/d StepBlinatumomab 90 µg/m²/dBlinatumomab Overall
LymphopeniaBlood and lymphatic system disorders3/126/136/67/916/324/442/76
EncephalopathyNervous system disorders0/120/130/62/92/322/46/76
Lipase increasedInvestigations0/120/130/60/90/321/41/76
ConvulsionNervous system disorders0/120/130/60/90/321/41/76
PyrexiaGeneral disorders0/123/130/60/94/320/47/76
AnaemiaBlood and lymphatic system disorders0/120/131/60/91/320/42/76
LeukopeniaBlood and lymphatic system disorders1/122/131/60/93/320/47/76
Catheter site infectionInfections and infestations0/121/131/61/91/320/44/76
PneumoniaInfections and infestations0/121/131/60/90/320/42/76
Upper respiratory tract infectionInfections and infestations0/120/131/60/90/320/41/76
Most frequent other events
Showing 10 of 230
Most frequent other events
EventBlinatumomab ≤ 5 µg/m²/dBlinatumomab 15 µg/m²/dBlinatumomab 30 µg/m²/dBlinatumomab 60 µg/m²/d FlatBlinatumomab 60 µg/m²/d StepBlinatumomab 90 µg/m²/dBlinatumomab Overall
PyrexiaGeneral disorders2/1211/136/69/926/324/458/76
ThrombocytopeniaBlood and lymphatic system disorders1/123/135/64/912/322/427/76
C-reactive protein increasedInvestigations5/125/135/66/912/323/436/76
Fibrin D dimer increasedInvestigations2/124/135/64/92/323/420/76
LymphopeniaBlood and lymphatic system disorders6/123/132/67/912/321/431/76
HyperglycaemiaMetabolism and nutrition disorders3/121/131/67/916/323/431/76
Protein total decreasedInvestigations0/120/130/62/95/323/410/76
Weight decreasedInvestigations3/125/132/61/911/323/425/76
Weight increasedInvestigations1/125/134/65/914/323/432/76
HeadacheNervous system disorders2/124/134/66/911/323/430/76

Baseline characteristics

Age, Continuous
Age, Continuous(years)Blinatumomab ≤ 5 µg/m²/dBlinatumomab 15 µg/m²/dBlinatumomab 30 µg/m²/dBlinatumomab 60 µg/m²/d FlatBlinatumomab 60 µg/m²/d StepBlinatumomab 90 µg/m²/dTotal
Mean66.8 ± 7.564.8 ± 8.053.3 ± 9.459.7 ± 11.957.1 ± 14.964.8 ± 5.660.3 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Blinatumomab ≤ 5 µg/m²/dBlinatumomab 15 µg/m²/dBlinatumomab 30 µg/m²/dBlinatumomab 60 µg/m²/d FlatBlinatumomab 60 µg/m²/d StepBlinatumomab 90 µg/m²/dTotal
Female241011119
Male1095921357
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Blinatumomab ≤ 5 µg/m²/dBlinatumomab 15 µg/m²/dBlinatumomab 30 µg/m²/dBlinatumomab 60 µg/m²/d FlatBlinatumomab 60 µg/m²/d StepBlinatumomab 90 µg/m²/dTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White12136932476
More than one race0000000
Unknown or Not Reported0000000
08

Study locations

5 sites
  • Medizinische Klinik 5, Hämatologie & Internistische Onkologie, Universitätsklinikum Erlangen
    Erlangen, 91054, Germany
  • Universitätsklinikum Essen, Klinik für Hämatologie, Medizinische Klinik und Poliklinik
    Essen, 45147, Germany
  • Universtätsklinkum Tübingen
    Tübingen, 72076, Germany
  • Universitätsklinikum Ulm, Abteilung Innere Medizin III
    Ulm, 89081, Germany
  • Medizinische Poliklinik der Julius-Maximilians-Universität Würzburg
    Würzburg, 97080, Germany
09

References and documents

Publications

  • Nagele V, Zugmaier G, Goebeler ME, Viardot A, Bargou R, Kufer P, Klinger M. Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomab. Exp Hematol. 2021 Aug;100:32-36. doi: 10.1016/j.exphem.2021.06.005. Epub 2021 Jul 3. PubMed 34228983 ↗
  • Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Blinatumomab, a Bispecific T-cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4. PubMed 27209293 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Aug 2011 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2006
First posted
Jan 11, 2006
Start
Jun 2004
Primary completionActual
Aug 2011
CompletionActual
Apr 2012
Results first posted
Jan 16, 2015
Last update
Jan 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00274742
Responsible party
Sponsor
First posted
Jan 11, 2006
Start date
Jun 2004
Primary completion
Aug 2011
Completion
Apr 2012
Results posted
Jan 16, 2015
Last update
Jan 16, 2015

Study contacts

Ralf Bargou, MD, PhD
principal investigator · Medizinische Poliklinik der Julius-Maximilians-Universität Würzburg, Zentrum für Innere Medizin, Oberdürrbacherstr. 6 D-97080 Würzburg

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion